A RETROSPECTIVE STUDY OF USAGE OF INJECTABLE METHYLCOBALAMIN IN 1401 CASES OF NEUROSPINAL DISEASES FROM THE YEAR 2015-2017

G. Satya Sravani^{*1}, Dr. P. Krishna Rajiv² & Dr. K. Vishnu Prasad³

^{*1}Vth year pharm.D, Aditya Pharmacy college, Surampalem, Andhra Pradesh,India ^{2&3}Consultant neurosurgeon

Abstract

Keywords: low back ache, occipital neuralgia, lumbar spondylosis, sciatica syndromes. **Background:** Methylcobalamin is an active molecule of vitamin B12 which can directly participate in homocysteine metabolism. Vitamin B12 may increase availability and effectiveness of noradrenaline and 5-hydroxytryptamine in the descending inhibitory nociceptive system. It is well established today, that methylcobalamin positively influences in the healing of various neurological and spinal diseases and improves pain scores in ultra-high blood levels.

Methodology: This is a retrospective clinical study. The study was done on 1401 patients cases between age group ranging from 16-70 and above 70 years treated on out-patient basis with cervicobrachial neuralgia, myofascial syndromes, lumbar spondylosis and sciatica syndromes. Some patients are excluded due to insufficient data. The data collected and validated by VAS Scale, with one month follow up are analysed.

Results: Among the 1401 patients, the majority study patients are females. 90-95% cases have grossly improved in their pain scores based on VAS Scale and also showed improvement in the physical wellbeing. It was also observed that intravenously Injectable methylcobalamin can also be safely given.

Conclusion: It was concluded and recommended that injectable methylcobalamin can be safely used in the Neurospinal diseases with excellent clinical result especially in the pain scores

Introduction

Methylcobalamin is an active molecule of vitamin B12 which can directly participate in homocysteine metabolism. It acts as a methyl donar and participates in the synthesis of S-adenosylmethionine, a nutrient that has powerful mood elevating properties. Vitamin B12 may increase availability and effectiveness of noradrenaline and 5-hydroxytryptamine in the descending inhibitory nociceptive system. Methylcobalamin that is ingested is not used directly as a cofactor, but is first converted by MMACHC into cob(II)alamin. Cob(II)alamin is then later converted into the other 2 forms, adenosylcobalamin and methylcobalamin for use as cofactors. That is, methylcobalamin is first dealkylated and then regenerated. Methylcobalamin is produced by some bacteria. It plays an important role in the environment. In the environment, it is responsible for the biomethylation of certain heavy metals. Methylcobalamin can be produced in the laboratory by reducing cyanocobalamin with sodium borohydride in alkaline solution, followed by the addition of methyl iodide.Normal values are 200 to 900 pico grams per milliliter (pg/mL).High doses of methylcobalamin are needed to regenerate neurons as well as the myelin sheath that protects nerve axons and peripheral nerves. It is well established today , that methylcobalamin positively influences in the healing of various neurological and spinal diseases and improves pain scores in ultra-high blood levels. It is



International Journal of Medical Research and Pharmaceutical Sciences

Volume 4 (Issue 10): October 2017ISSN: 2394-9414DOI- 10.5281/zenodo.1003164Impact Factor- 3.109with high dose B12 injections is not only completely safe but fortunately also very effective. With the right
treatment patients can recover completely. Starting straight away with treatment is essential, as is the continuing
treatment in order to give the body enough B12 to fully recover. Therefore it is essential that patients are no longer
exposed to the real danger of irreversible symptoms because of the imaginary fear of overdosing.

Objectives

To review the clinical efficacy and safety of mecobalamin in the treatment of cervicobrachial neuralgia, myofascial syndromes, lumbar spondylosis and sciatica syndromes.

Methadology

This is a retrospective clinical study. The study was done on 1401 patients cases between age group ranging from 16 70 and above 70 years treated on out-patient basis with cervicobrachial neuralgia, myofascial syndromes, lumbar spondylosis and sciatica syndromes from June 2015- May 2017. Some patients are excluded due to insufficient data. The treatment includes 1500mcg once in 2 days. The data collected and validated by VAS Scale. Followed up for 2 years to 1 month and analysed.

S.NO	AGE	GENDER
1	48	MALE
2	34	MALE
3	44	MALE
4	32	FEMALE
5	33	FEMALE
6	47	FEMALE
7	32	FEMALE
8	30	FEMALE
9	48	FEMALE
10	24	MALE
11	55	FEMALE
12	36	MALE
13	45	FEMALE
14	48	MALE
15	36	FEMALE
16	47	MALE
17	41	MALE
18	42	MALE
19	25	MALE
20	39	MALE
21	60	FEMALE
22	36	FEMALE
23	62	FEMALE
24	30	FEMALE
25	35	
26	54	MALE
27	40	FEMALE
28	55	MALE
29	45	FEMALE
30	64	MALE
31	62	FEMALE
32	75	MALE
33	40	MALE
34	26	FEMALE
35	32	MALE
36	65	MALE
37	35	MALE
38	24	FEMALE
20	1	RAAS E

21	60	FEMALE
22	36	FEMALE
23	52	FEMALE
24	30	FEMALE
25	35	MALE
26	14	MALE
27	40	FEMALE
28	- 55	MALE
29	45	FEMALE
30	.64	MALE
31	62	FEMALE
32		MALE
33	40	MALE
34	24	FEMALE
35	32	MALE
36	65	MALE
37	35	MALE
38	24	FEMALE
39	53	MALE
40	58	FEMALE
41	87	MALE
42	50	FEMALE
43	31	MALE
44	62	FEMALE
45	68	FEMALE
46	67	FEMALE
47	62	FEMALE
48	48	FEMALE
49	40	MALE
50	62	FEMALE
51	37	FEMALE
52	32	FEMALE
53	62	MALE
54	31	MALE
55	57	MALE
56	53	FEMALE
57	60	FEMALE
58	66	MALE



131	52	FEMALE			
132	48	FEMALE	168	52	FEMALE
133	45	MALE	169	40	FEMALE
134	31	MALE	170	66	MALE
135	33	FEMALE	171	34	FEMALE
136	34	FEMALE	172	52	FEMALE
137	34	MALE	173	48	MALE
138	45	FEMALE	174	42	FEMALE
139	32	FEMALE	175	42	FEMALE
140	42	FEMALE	176	32	FEMALE
140	50	FEMALE	177	43	MALE
141	46	FEMALE	178	34	MALE
		and the second se	179		FEMALE
143	42	FEMALE	180	42	FEMALE
144	58	MALE	181		FEMALE
145	51	FEMALE	182	42	FEMALE
146	豜	MALE	183		FEMALE
147	47	FEMALE	184	59	FEMALE
148	50	FEMALE	185	38	FEMALE
149	50	MALE	186	44	MALE
150	30	FEMALE	187	32	FEMALE
151		MALE	188	33	FEMALE
152		FEMALE	189	38	MALE
153	47	FEMALE	190	42	FEMALE
154	42	MALE	191	49	MALE
155	32	MALE	192	42	FEMALE
156	71	MALE	193	58	FEMALE
150	42	and the second se	194	36	FEMALE
157		MALE	195	10	FEMALE
	32	MALE	196	32	FEMALE
159	34	MALE	197	43	FEMALE
160		FEMALE	198	42	FEMALE
161	52	FEMALE	199		FEMALE
162	42	MALE	200	- 22	MALE
163	42	FEMALE	201	36	MALE
164	32	FEMALE	202	10	FEMALE
165	40	MALE	203	48	MALE
166	45	MALE	204	40	MALE
167	62	FEMALE	705	45	MAI F
168	52	FEMALE			



DOI-10.5281/zenodo.1003164

Impact Factor- 3.109

206	65	MALE
207	32	FEMALE
208	44	FEMALE
209	45	FEMALE
210	70	FEMALE
211	58	MALE
212	33	FEMAL
213	54	MALE
214	32	FEMALE
215	38	FEMALE
216	42	FEMALE
217	32	FEMALE
218	- 22	FEMALE
219		FEMALE
220	46	FEMALE
221	34	FEMALE
222	30	FEMALE
223	60	FEMALE
224	67	MALE
225	48	FEMALE
226	30	FEMALE
227	42	FEMALE
228	56	FEMALE
229	60	FEMALE
230	50	FEMALE
231	31	MALE
232	62	MALE
233	22	MALE
234	60	FEMALE
235	46	MALE
236	32	MALE
237	52	MALE
238	40	MALE
239	43	FEMALE
240	60	FEMALE
241		FEMALE
242		FEMALE
243		FEMALE

244	36	FEMALE
245	38	FEMALE
246	34	MALE
247	47	FEMALE
248	32	MALE
249	60	FEMALE
250	35	MALE
251	28	MALE
252	56	MALE
253	50	FEMALE
254	67	MALE
255	36	FEMALE
256	65	MALE
257	32	MALE
258	47	FEMALE
259	58	MALE
260	33	MALE
261	40	FEMALE
262	44	MALE
263	29	MALE
264	48	FEMALE
265	46	FEMALE
266	45	FEMALE
267	42	FEMALE
268	42	FEMALE
269	30	FEMALE
270	32	MALE
271	60	MALE
272	41	FEMALE
273	69	FEMALE
274	54	MALE
275	39	MALE
276	42	MALE
277	49	FEMALE
278	32	MALE
279	40	FEMALE
280	42	MALE
281	40	FFMAI F



Impact Factor- 3.109

281	40	FEMALE	319	74	PERSON P
282	26	FEMALE	319	70	FEMALE
283	32	FEMALE	320	48	FEMALE
284	24	MALE	321	33	and the second se
285	63	FEMALE	323	42	MALE
286	40	MALE	323	40	FEMALE
287	42	MALE	324	40	
288	54	FEMALE	325	50	FEMALE
289	62	FEMALE	320	65	FEMALE
290	42	FEMALE	328	50	FEMALE
291	49	MALE	328	50	FEMALE
292	60	FEMALE	330		MALE
293	62	MALE	330	- 25	MALE
294	22	FEMALE	331		FEMALE
295		FEMALE	333	40	FEMALE
296	39	MALE	334	32	FEMALE
297	69	FEMALE	335	50	MALE
298	64	FEMALE	336	42	FEMALE
299	44	MALE	337	60	MALE
300	-	FEMALE	338	37	MALE
301	39	MALE	339	48	MALE
302	37	FEMALE	340	42	MALE
302	34	MALE	341		FEMALE
303	45	FEMALE	342	40	FEMALE
305		FEMALE	343	100	MALE
306	44	FEMALE	344	64	FEMALE
307	50	FEMALE	345	49	FEMALE
308		MALE	346	43	FEMALE
308	62	FEMALE	347	64	MALE
310	02	MALE	348	43	MALE
310	67	MALE	349	50	FEMALE
312	42		350	31	MALE
312	64	MALE	351	40	MALE
313	34	MALE	352	45	MALE
	34	FEMALE	353	47	FEMALE
315		MALE	354	50	FEMALE
316		MALE	355	38	MALE
317	32	MALE FEMALE	356	46	FFMALF



DOI- 10.5281/zenodo.1003164

357	63	FEMALE	394	39	FEMALE
358	49	FEMALE	395	29	FEMALE
359	42	FEMALE			
360	50	FEMALE	396	61	FEMAL
361	57	FEMALE	397	43	FEMAL
362		FEMALE	398	50	-
363	66	MALE		1.5.5.5	FEMAL
364	66	MALE	399	43	FEMAL
365	53	FEMALE	400	45	FEMAL
366	38	FEMALE	-		
367	32	FEMALE	401	65	FEMAL
368	69	MALE	1 C C C C C C C C C C C C C C C C C C C		
369	43	MALE			
370	32	FEMALE			
371	38	FEMALE			
372	32	MALE			
373	65	MALE	2 <u>5</u> (2		
374	67	MALE	MALE	16	2
375		MALE			-
376	51	FEMALE	EMALES	23.	4
377	50	FEMALE			
378	48	MALE			
379	60	MALE			
380	48	MALE	ELOW 20	-	2
381	60	FEMALE			
382	63	FEMALE	1-30	4	-
383	48	MALE	1-40	10	6
384	40	FEMALE		11	-
385	40	FEMALE	1-50		-
386	45	FEMALE	1-60	7.	4
387	57	MALE	1-70	5	1
388	65	FEMALE	-		-
389	53	MALE	1-80		5
390	50	FEMALE	BOVE 80		1
391	57	MALE	DUIE OU		-
392	68	FEMALE			
393	42	MALE EEMALE			



		-	1.1		1000
118	ABAR SPONDYLOS	20	36	32	MALE
S.NO	AGE	GENDER	37	34	MALE
1	100	MALE	38	61	FEMALE
2	42	FEMALE	39	65	FEMALE
3		FEMALE	40	36	FEMALE
4		MALE	41	28	FEMALE
5	53	MALE	42	62	FEMAL
6	65	MALE	43	35	MALE
7	40	MALE	44	48	FEMALI
8		MALE	45	32	MALE
9	53	FEMALE	46	49	FEMALE
10	78	FEMALE	47	61	MALE
11	42	MALE	48	46	MALE
12	63	MALE	49	36	MALE
13	28	FEMALE	50	36	FEMAL
14	62	MALE	51		MALE
15		MALE	52	48	FEMALE
16	54	FEMALE	53	50	MALE
17	34	MALE	54	28	MALE
18	63	FEMALE	55	81	MALE
19	39	MALE	56		MALE
20	42	FEMALE	57	61	MALE
21	57	FEMALE	58	(BE - C	MALE
22	63	MALE	59	35	MALE
23	20	FEMALE	60	40	FEMAL
24	34	MALE	61.	38	MALE
25	34	FEMALE	62	48	FEMAL
26	37	MALE	63	48	FEMAL
27	32	FEMALE	64	47	FEMAL
28	40	FEMALE	65	54	MALE
29	56	MALE	66	66	MALE
30	28	MALE	67	33	FEMALE
31	10	FEMALE	68	48	FEMAL
32	49	MALE	69	50	MALE
.33	54	FEMALE	70	23	MALE
34	31	FEMALE	71	45	MALE
35	47	MALE	72	64	MALE
			73	24	ANAL E



Impact Factor- 3.109

MALE FEMALE FEMALE MALE MALE FEMALE FEMALE FEMALE FEMALE FEMALE MALE FEMALE MALE MALE MALE MALE FEMALE FEMALE MALE MALE FEMALE MALE FEMALE FEMALE MALE MALE FEMALE FEMALE MALE FEMALE MALE MALE MALE MALE MALE FEMALE MALE

74	- 15	MALE	144	
75	62	MALE	111	
76	UL.	FEMALE	112	44
77		FEMALE	113	35
78	45	MALE	114	30
79	42	MALE	115	45
80	61	MALE	117	95
81	01	FEMALE	118	32
82	46	FEMALE	119	JE.
83	62		120	60
84	45	MALE	121	58
85	the second se	MALE	122	52
	28	FEMALE	123	38
86	33 35	MALE	124	55
		MALE	125	43
88	48	MALE	126	47
89	54	MALE	127	24
90	40	MALE	128	36
91		FEMALE	129	- 25
92	18	MALE	130	76
93	38	MALE	131	Û
94	45	MALE	132	32
95	4	MALE	133	11
96	55	FEMALE	134	38
97	46	MALE	135	50
98	38	MALE	136	49
99	33	MALE	137	36
100	65	MALE	138	
101	49	MALE	139	32
102	40	FEMALE	140	53
103	45	FEMALE	141	
104	37	MALE	142	
105	64	FEMALE	143	11
106	60	FEMALE	144	35
107	79	FEMALE	145	
108	ži.	FEMALE	146	42
109	44	FEMALE	147	32
110	2	FEMALE		
111		LAN E		



149		11115	187	- 22	MALE
		MALE	188	38	FEMAL
150	0.0	FEMALE	189	22	FEMAL
151	38	MALE	190	30	FEMAL
152	41	MALE	191	40	FEMAL
153	58	MALE	192	45	FEMAL
154		FEMALE	193	37	MALE
155		MALE	194	64	FEMAL
156	- 28	FEMALE	195	60	FEMAL
157	32	MALE	196	33	MALE
158	56	MALE	197	55	FEMAL
159	47	MALE	198	46	MALE
160	45	FEMALE	199	26	MALE
161	22	FEMALE	200	42	FEMAL
162	37	MALE	201	24	FEMAL
163		FEMALE	202	85	FEMAL
164	62	MALE	203	55	MALE
165	38	FEMALE	204	52	MALE
166	40	MALE	205	32	MALE
167	35	FEMALE	206	53	FEMAL
168	33	FEMALE	207	22	FEMAL
169		MALE	208	38	FEMAL
170	86	FEMALE	209	69	FEMAL
171	65	FEMALE	210	37	MALE
172	52	FEMALE	211	63	MALE
173	35	MALE	212	32	FEMAL
174	40	MALE	213	42	MALE
175	32	FEMALE	214	30	FEMAL
176		FEMALE	215	43	FEMAL
177	45	FEMALE	216		MALE
178	32	FEMALE	217	- 201	FEMAL
179	77	FEMALE	218	28	MALE
180		MALE	219	42	MALE
181	45	MALE	220	50	MALE
182	52	MALE	221	42	MALE
183	38	MALE	222	48	MALE
184	43	MALE	223	39	FEMAL
185	70	FEMALE	224	30	MALE
186	10	MALE			



International Journal of Medical Research and Pharmaceutical Sciences Volume 4 (Issue 10): October 2017 ISSN: 2394-9414 DOI-10.5281/zenodo.1003164 Impact Factor- 3.109

225	46	MALE	262	3	FEMALE
225		MALE	263	72	FEMALE
227	10	FEMALE	264		MALE
228	42	FEMALE	265	\$3	FEMALE
229	44		265	34	MALE
	74	MALE	267	56	FEMALE
230	50	FEMALE	268	53	FEMALE
231		MALE	269	48	MALE
232	68	MALE	270	48	FEMALE
233		MALE	271	31	FEMALE
234	39	MALE	272	28	FEMALE
235	48	MALE	273	40	FEMALE
236	22	MALE	274	32	MALE
237		MALE	275	31	FEMALE
238	62	MALE	276	42	MALE
239	57	FEMALE	277	70	MALE
240	37	MALE	278		FEMALE
241	32	FEMALE	279	32	FEMALE
242	34	MALE	280	35	MALE
243	46	MALE	281	62	MALE
244	33	FEMALE	282	77	MALE
245	61	MALE	283	52	MALE
245	39	MALE	284	32	FEMALE
247	3	MALE	285	48	FEMALE
248	53	MALE	285	32	FEMALE
249	36	FEMALE	287	43	MALE
250	35	FEMALE	288	32	MALE
251	26	FEMALE	289	36	MALE
252	62	MALE	290	60	FEMALE
253	48	MALE	291	40	MALE
254	2	MALE	292	-41	FEMALE
255	41	FEMALE	293	32	MALE
256	34	FEMALE	294	6	FEMALE
257	32	MALE	295	12	MALE
258	63	MALE	295	54	FEMALE
259		MALE	290	32	MALE
			297	66	FEMALE
260		MALE	298	46	
261	42	FEMALE EEMAN E	299	40	FEMALE



DOI-10.5281/zenodo.1003164

			r
3	1.20	NE	Ļ
B	1	ME	ł
E	4	RIAL	Ļ
第		ERE	Ļ
в		MAE	ļ
15 15		FIRE	Ļ
直	I	RME	Ļ
12	1	RIKE	L
101 102	4	MAE	Ļ
в	1	EWE	l
第	I	RIKE	L
31	1.1	HE.	ļ
莨		EIAE	l
25	I	NE.	L
31	1.1	BE.	L
35		IRE .	L
	1	NE.	1
28 27		BRE .	L
10 10 10 10 10 10	3	ENE	L
29	1	EIRE	L
22	T.	BLE .	Į
10	ž	WE	L
12	1. F .	RIKE	1
15	100	WE	L
10		FIRE	L
苾	1	WE	1
3	1 ^m	NAE .	L
17	1	ENE	L
3	1	WE	
29	3	INE	
13	-	SEE.	L
푠		NA.E	Ĺ
Ŧ		NE.	
器	9	NE.	
14 15 15 15 14 15 15 14 15 15 14 15 15 15 14 15 15 15 15 15 15 15 15 15 15 15 15 15	2	HE HE	ĺ
TK.	4	NE.	
Th		EWE	
12	5.6	THE	ſ

13	- 11	MAE
25	ę	WAE
36	0	MAE
341	4	FDALE
30		FEMALE
16	6	EWE
34	46	FEMALE
35	1	WE
38	40	WALE
30	¥.	WALE
14	Q	MAE
36	1	MALE
沒	4	EMAE
251	茸	FEWRE
迎	*	FEMALE
四	12	FEWAE
湖	4	FBIRE
斑	12	MALE
斑	1	FEMALE
2	1	WAE
22	茸	MALE
斑	효	W.E
21		FEMALE
周	荁	MAE
题	1	MALE
10	il	WAE
展	E	WAE
服	1	WAE
浙	111	EWAE
30	茸	MAE
32		WAE
100	12	WE
調加	2	WAE
町	8	WE
22:	王	WAE
页 34	6 4	WE
314	4	EMALE
15		WAE



376	32	MALE	414	42	FEMALE
377	- 26	MALE	415	32	
378	52	FEMALE	415	34	FEMALE
379	53	FEMALE	410	10	and the second se
380	4	MALE		32	MALE
381	40	MALE	418	43	MALE
382	58	MALE	419	48	FEMALE
383	50	MALE	420	41	MALE
384	32	FEMALE	421		FEMALE
385		FEMALE	422	42	MALE
386	40	FEMALE	423	44	MALE
387	32	FEMALE	424	74	FEMALE
388		FEMALE			FEMALE
389	37	FEMALE	426	43	FEMALE
390		FEMALE	427	32	FEMALE
391		FEMALE	428		FEMALE
392	- 68	MALE	429		FEMALE
393	12	FEMALE	430	32	MALE
394	62	FEMALE	431	36	FEMALE
395	10	FEMALE	433	51	FEMALE
3%6	42	FEMALE	433	44	FEMALE
397	40	FEMALE	434	6	FEMALE
398	47	MALE	436	00	FEMALE
399	0	FEMALE	430		MALE
400	45	FEMALE	438	49	MALE
401	32	MALE	439	97	MALE
402	46	FEMALE	440	45	MALE
403	Constant of the local division of the local	FEMALE	44)	35	MALE
404	47	FEMALE	442	36	FEMALE
405	40	MALE	443	32	MALE
406	Contraction of the local division of the loc	FEMALE	444	32	FEMALE
407	82	FEMALE	445	43	MALE
408	42	MALE	445	60	FEMALE
409	32	FEMALE	447	34	MALE
410	45	MALE	448	63	MALE
411	34	MALE	449	<i>iii</i>	FEMALE
412	4)	FEMALE	450	42	MALE
812	1	NALE STATE	129.	42	EEMAN E



DOI-10.5281/zenodo.1003164

452	62	MALE	490	11	FEMALE
453	32	MALE	491	3	MALE
454		MALE	492	42	MALE
455		MALE	493	51	MALE
456	34	MALE	494	30	FEMALE
457	31	FEMALE	495	32	FEMALE
458	32	MALE	496	52	MALE
459	50	MALE	497	55	MALE
460	48	FEMALE	498	37	MALE
461		MALE	499	42	MALE
462	66	MALE	500	53	MALE
463	47	MALE	501	32	MALE
464	32	MALE	502	ii ii	FEMALE
465	43	MALE	503	40	FEMALE
465	52	FEMALE	504	. 70	FEMALE
467	32	MALE	505	45	FEMALE
468	61	MALE	506	32	MALE
469	62	MALE	507	38	MALE
470	43	MALE	508	34	FEMALE
471	42	MALE	509	43	MALE
472	33	MALE	510	34	MALE
473	68	FEMALE	511	29	MALE
474	38	FEMALE	512	44	FEMALE
475	60	FEMALE	513	#	MALE
476	58.	FEMALE	514		FEMALE
477	48	MALE	515	63	FEMALE
478	48	MALE	516	42	MALE
479	24	MALE	\$17	39	MALE
480	32	FEMALE	518	- \$7	MALE
481	45	FEMALE	519	57.	MALE
482	32	FEMALE	520		FEMALE
483	1	FEMALE	521	42	FEMALE
484	42	MALE	\$22	48	MALE
485	50	MALE	523	21	FEMALE
486	32	MALE	524	- 8	MALE
487	34	MALE	525	47	MALE
488	37	MALE	526	62	MALE
489	54	FEMALE	527	45	FEMALE



528	1	FEMALE	565	-	MALE
529		MALE	566	-40	FEMALE
530		FEMALE	567		FEMALE
531		MALE	568	45	FEMALE
532		FEMALE	569	63	FEMALE
533	50	FEMALE	570	40	
\$34	49	MALE	571		MALE
535	60	FEMALE		32	FEMALE
536		MALE	572	42	FEMALE
\$37	22	FEMALE	573	42	FEMALE
538	42	FEMALE	574	61	FEMALE
539	36	FEMALE	575	50	MALE
540	22.	MALE	576		FEMALE
541	39	FEMALE	577	:41	FEMALE
542	1	MALE	578		MALE
543	34	FEMALE	579		MALE
544	47	FEMALE	580	33	MALE
545	50	FEMALE	581	36	MALE
546	32	MALE	582	, ă	MALE
547	49	FEMALE	583	47	MALE
548	42	MALE	584	湯	MALE
549	22	MALE	585	38	MALE
550	42	MALE	586	- 22	FEMALE
551		MALE	587	10	FEMALE
552	61	FEMALE	588	40	FEMALE
553	- 19	MALE	589	14	FEMALE
554	48	MALE	590	43	MALE
555	11	FEMALE	591	18	MALE
556	40	FEMALE	592	-33	FEMALE
557	9	FEMALE	593	45	MALE
558	38	FEMALE	594	9	FEMALE
559	40	MALE	595	X	FEMALE
560	42	MALE	596	47	MALE
561	and the second second	FEMALE	597	1	MALE
562	32	FEMALE	598	10	FEMALE
563	43	MALE	599	45	MALE
564		FEMALE	600	46	FEMALE
565		MALE	601	45	FEMALE
			602	68	MALE



DOI-10.5281/zenodo.1003164

603	46	FEMALE
604	50	FEMALE
605	48	MALE
606	X	FEMALE
607	3	FEMALE
608	- 12	FEMALE
609	10	FEMALE
610	33	FEMALE
611	40	MALE
612	66	MALE
613	32	FEMALE
614	40	FEMALE
615	32	FEMALE
616	49	MALE
617	65	MALE
618	65	FEMALE
619		FEMALE
620	4	FEMALE
621	62	MALE
622	34	FEMALE
623	47	MALE
624	0	FEMALE
625	4)	MALE
625	22	FEMALE
627	븲	MALE
628	49	MALE
629	43	MALE
630		FEMALE
631	- 48	FEMALE
632	42	MALE
633	65	FEMALE
634	62	FEMALE
635	14	FEMALE
636	1	FEMALE
637	42	FEMALE
638	32	MALE
639	.40	FEMALE
640	11	MALE

641	43	FEMALE
642	50	FEMALE
643	32	FEMALE
644	57	FEMALE
645	84	MALE
646	44	MALE
647	70	MALE
648	32	MALE
649	42	FEMALE
650	58	FEMALE
651	48	MALE
652	35	FEMALE
653	45	MALE
654	65	MALE
655	32	FEMALE
656	70	MALE
657	61	FEMALE
658	39	MALE
659	35	MALE
660	42	FEMALE
661	32	FEMALE
662	32	FEMALE
663	42	MALE
664		FEMALE
665	25	FEMALE
666	65	FEMALE
667		FEMALE
668	43	MALE
669	78	MALE
670	34	MALE
671	44	MALE
672	38	MALE
673	31	MALE
674	32	MALE
675	25	FEMALE
676	50	FEMALE
677	31	MALE
678	45	MALE



INVICORE	AACHAN, NEL	MALCOA.
5.N0	AGE	GENERR
1.	3.0	PEMALE
- 2	43	FEMALE
3	42	FEMALE
. 4	42	FEMALE
- 5	49	MALE.
	43	FEMALE
3		FEMALE
	14	FEMALE
	47	MALE
10.	1.01	MALE
11		FEMALE
12		FEMALE
13	40	MALE
.14	21	MALE
18	38.	FEMALE
14	43	MALE
17	12	MALE.
18	42	FEMALE
19.		ANALE.
20	42	FEMALE
21	40	MALE
22		MALE
23	40	FEMALE
24	24	FEMALE
- 25	47	FEMALE
24		MALE
27	48	FEMALE
28	43	FEMALE
29	35	FEMALE
	0.00	FEMALE
31	48	FEMALE
20		MALE
33		FEMALE
34		MALE
28	28	FEMALE
	-	10.01.0



37	62	FEMALE	73		FEMALE
38	24	MALE	N	41	MALE
39		FEMALE		3	MALE
40	42	MALE	71	31	MALE
41	31	MALE	73		TEMLE
42	- 60	FEMALE	前	- 18	10AAG1
43		MALE	11		MALE
44	32	FEMALE	12		MALE
45	.56	MALE	- 11		12ANGF
46		FEMALE	14		1.ANDP
- 47	33	FEMALE	15	4	FD44.1
.48	12	FEMALE			10MUE
40		FEMALE	\$7		WALE
50	62	MALE			MALE
51	32	MALE	19		FEMALE
52	100	MALE	10	财	MALE
53	32	MALE	\$1	40	MALE
54	44	MALE	10	п	TIMOT
55	49	FEMALE	41		(DAL)
56	31	MALE	94		MALE
57	32	MALE		34	TIMUT
58	62	FEMALE	W.		FDMALE
59	65	MALE	- (t)		MALE
60	42	FEMALE	N	ж	TEMMET
61	46	FEMALE	91	1	MALE
62	62	MALE	105	10	TEMALE
63	47	FEMALE	101	4	f0441
64	65	MALE	102	- 40	TERRIE
65	54	MALE	503	- '44	1,440
66	39	MALE	104	43	1.JAMGH
67	54	FEMALE	105		FEMALE
68	43	FEMALE	106	4	WALE
69	45	FEMALE	101		NALE
70	38	FEMALE	108		MALE
71	37	MALE	109	-	MALE
72	.47	MALE	170		11AMOT
73	50	FEMALE	111	0	1441
34	5.5	PERSON P.	112	- 10	HDMAL!

112	50	FEMALE
113	35	FEMALE
114	22	FEMALE
115	32	FEMALE
116	60	FEMALE
117	43	MALE
118	57	MALE
119	53	MALE
120	32	FEMALE
121		FEMALE
122	32	MALE
123	(44)	FEMALE
124	32	MALE
125	48	MALE
126	28	FEMALE
127	49	MALE
128		MALE
129	68	FEMALE
130	50	MALE
131	41	FEMALE
132	50	FEMALE
133	-22	FEMALE
134	36	FEMALE
135	38	MALE
136	42	FEMALE
137		FEMALE
138	79	MALE
139	32	MALE
140	38	FEMALE
141	50	FEMALE
142	61	MALE
143	40	FEMALE
144	40	FEMALE
145	65	MALE
1.46	29	FEMALE
147	.38	FEMALE
148	46	FEMALE
149	100	MALE

150	61	MALE
151	65	FEMALE
152	-45	MALE
153	42	MALE
154	33	MALE
158	62	MALE
156	63	MALE
157	11	FEMALE
158	32	FEMALE
159	1000	MALE
160	50	FEMALE
161	10	MALE
167	33	MALE
163	32	FEMALE
164	-14	FEMALE
165		FEMALE
160	45	FEMALE
160	38	MALE
165	-30	FEMALE
160	79	
170	41	FEMALE
170		the second s
	38	MALE
172	33	MALE
173	82	
174		10170-0
175	32	MALE
176	35	FEMALE
177	34	FEMALE
178		FEMALE
179		MALE
180	58	MALE
181	34	MALE
187	36	FEMALE
183	40	FEMALE
184	48	MALE
185	. 44	MALE
186		FEMALE
		FEMALS



188	33	MALE			
189		MALE	226	42	FEMA
190	54	MALE	227	35	FEMA
191	42	MALE	228	45	FEMA
192	42	FEMALE	229	35	MAL
193		MALE	230	60	MAL
194	31	FEMALE	231	41	FEMA
195	32	MALE	232	32	MAL
196	42	FEMALE	233	45	FEMA
197	32	FEMALE	235	32	FEMA
198	34	FEMALE	234		FEMA
199	59	MALE	235	42	
200	40	FEMALE			MAL
201	38	FEMALE	237	24	FEMA
202	42	MALE	238	32	MAL
203	39	FEMALE .	239	58	MAL
204	49	MALE	240	53	FEMA
205		FEMALE	241	40	MAL
206	56	FEMALE	242	44	MAL
207	40	MALE	243	40	FEMA
208	42	FEMALE	244	40	FEMA
209		FEMALE	245	53	FEMA
210	62	FEMALE	246	36	MAL
211	46	FEMALE	247	42	MAL
212	40	MALE			
213		FEMALE			
214	45	FEMALE			
215	32	MALE	BELOW 20	4	
216	46	MALE	21-30	29	-
217	50	FEMALE	31-40	77	-
218	53	MALE	41-50	63	-
219	52	FEMALE	51-60	50	+
220	52	FEMALE	61-70	22	-
221	52	MALE	71-80	1	+
222	51	MALE	ABOVE 80	1	-
223	42	FEMALE	ABUVE 80	1	-
224	52	MALE		110	-
225	54	FEMALE .	FFMALES	110	-

DISEASE	AGE GROUP
SCIATICA	41-50
MYOFASCIAL SYNDROME	41-50
LUMBAR SPONDYLOSIS	31-50
CERVICOBRANCHIAL NEURALGIA	31-50

Sciatica Syndrome

Sciatica is the pain radiating along the sciatic nerve, which runs down one or both legs from the lower back. Among the 401 Sciatica patients majority of the patients are females and between the age group of 41-50.

Myofascial Syndrome

Myofascial pain refers to pain caused by muscular irritation. The large upper back muscles are prone to developing myofascial pain that radiates from sensitive points, called trigger points throughout muscle tissue. Muscular



International Journal of Medical Research and Pharmaceutical Sciences


Volume 4 (Issue 10): October 2017ISSN: 2394-9414DOI- 10.5281/zenodo.1003164Impact Factor- 3.109irritation and upper back pain is due to muscle weakness and repetitive motions., Among the 48 Myofascialsyndrome patients the majority of patients are males and betweem the age group 41-50.

Cervicobranchial Neuralgia

Cervicobrachial Neuralgia is a syndrome associated with the inflammation of the brachial plexus. The term 'cervicobrachial' means relating to the neck and arm, while the term 'brachial neuralgia' generally refers to the pain associated with brachial plexus injury., Among the 247 patients majority of patients are females and between the age group 31-40.


Lumbar Spondylosis


Lumbar Spondylosis is a medical condition in which chronic pain is experienced by the patient in the lower back. Among the 705 patients majority of patients are males and between the age 31-40



21







Results

Out of total 1401 patients, higher proportion (50.3%) were found to have lumbar spondylosis followed by 28.6% patients with sciatica, 17.6% patients with cervicobranchial neuralgia and 3.5% suffering from myofascial syndrome.

Among lumbar spondylosis patients, mean age was found to be 42.87 ± 13.90 with majority (28.7%) of them in the age group 31 - 40 years and about half of them (54%) were males.

Among the patients diagnosed with sciatica, the mean age was 45.48 ± 12.73 with higher proportion (29.2%) of the patients in the age group 41-50 years and 57.8% females.


The mean age of patients with cervicobranchial neuralgia was 43.58 ± 12.11 and most of them (31.2%) were in the age group 31 - 40 years. About 55.4% of the patients were females

International Journal of Medical Research and Pharmaceutical Sciences

Volume 4 (Issue 10): October 2017ISSN: 2394-9414DOI- 10.5281/zenodo.1003164Impact Factor- 3.109Of the 48 patients diagnosed with myofascial syndrome, majority were males (62.5%) and in the ages group 41-50

Of the 48 patients diagnosed with myofascial syndrome, majority were males (62.5%) and in the ages group 41-50 years (31.2%). The mean age of these patients was 44 ± 12.45 .

Around 90 - 95% of the patients were shown to have improvement on VAS pain scale along with improvement in physical wellbeing.



Conclusion

It was concluded and recommended that injectable methylcobalamin can be safely used in the Neurospinal diseases with excellent clinical result especially in the pain scores.

References

- 1. https://en.wikipedia.org/wiki/Methylcobalamin
- 2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4759374/
- 3. http://www.prohealth.com/library/showarticle.cfm?libid=481
- 4. https://stichtingb12tekort.nl/wetenschap/stichting-b12-tekort-artikelen/english/treatment-with-high-dose-vitamin-b12-been-shown-to-be-safe-for-more-than-50-years
- 5. Bhavani Jayabalan, Lian Leng Low. Vitamin B supplementation for diabetic peripheral neuropathy. Singapore Med J 2016; 57(2): 55-59.
- 6. *Health watch. Methylcobalamin: A Potential Breakthrough in Neurological Disease.1999.Source: [Internet]. Available from: http://www.prohealth.com/library/showarticle.cfm?libid=481*
- 7. Treatment with high dose vitamin B12 been shown to be safe for more than 50 years. Source: [Internet].
- 8. Ming Zhang, Wenjuan Han, Sanjue Hu, and Hui Xu. Methylcobalamin: A Potential Vitamin of Pain Killer. Hindawi Publishing Corporation Neural Plasticity 2013; 1-6